Pembrolizumab with PS2 lung cancer patients

JavaScript isn't enabled in your browser, so this file can't be opened. Enable and reload.

On behalf of the PePS2 investigators, we would be most grateful if you would take a minute or two to complete this short survey which will be of significant importance in any decision to try to get access for our PS2 lung cancer patients to pembrolizumab through NICE, a group who as you know are not currently included in the NICE criteria for pembrolizumab.

Our request to NICE is based upon the recent publication of PePS2 trial, the abstract of which can be found at the link below; the full paper is also freely available with a simple registration, or we can provide this by emailing peps2@trials.bham.ac.uk. In essence, it shows that pembrolizumab is well tolerated and has very acceptable levels of activity particularly in patients with PD-L1 positive cancers.

Gary Middleton , Kristian Brock, Joshua Savage, Rhys Mant, Yvonne Summers, John Connibear, Riyaz Shah, Christian Ottensmeier, Paul Shaw, Siow-Ming Lee, Sanjay Popat, Colin Barrie, Gloria Barone, Lucinda Billingham. Pembrolizumab in patients with non-small-cell lung cancer of performance status 2 (PePS2): a single arm, phase 2 trial. Lancet Respir Med 2020 Sep;8(9):895-904. doi: 10.1016/S2213-2600(20)30033-3. Epub 2020 Mar 19.
https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(20)30033-3/fulltext

Current role *

Consultant oncologist

Specialist registrar

Research nurse

Other:

In PD-L1 >50% TPS PS2 patients would you prescribe pembrolizumab first-line if there were no contra-indications to checkpoint blockade? *

In preference to first-line chemotherapy

As a therapy option as you do not routinely prescribe chemotherapy first-line to PS2 patients

I would be unlikely to

I never would

In PD-L1 TPS >50% PS2 patients would you prescribe pembrolizumab second-line if there were no contra-indications to checkpoint blockade? *

In preference to second-line chemotherapy

As a therapy option as you do not routinely prescribe second-line chemotherapy to PS2 patients

I would be unlikely to

I never would

In PD-L1 TPS 1-49% PS2 patients would you prescribe pembrolizumab first line if there were no contra-indications to checkpoint blockade? *

In preference to first-line chemotherapy

As a therapy option as you do not routinely prescribe chemotherapy first line to PS2 patients

I would be unlikely to

I never would

In PD-L1 TPS 1-49% PS2 patients would you prescribe pembrolizumab second-line if there were no contra-indications to checkpoint blockade? *

In preference to second-line chemotherapy

As a therapy option as you do not routinely prescribe second-line chemotherapy to PS2 patients

I would be unlikely to

I never would

Do you think on the basis of this data that pembrolizumab should be approved as a therapeutic option for PS2 NSCLC patients with PD-L1 TPS >50%? *

Strongly agree

Agree

Data not strong enough to persuade me

Disagree

Strongly disagree

Do you think on the basis of this data that pembrolizumab should be approved as a therapeutic option for PS2 NSCLC patients with PD-L1 TPS 1-49%? *

Strongly agree

Agree

Data not strong enough to persuade me

Disagree

Strongly disagree

Submit

Clear form

Never submit passwords through Google Forms.

This content is neither created nor endorsed by Google. Report Abuse - Terms of Service - Privacy Policy

Forms